Lilly Launches Physician Payment Registry

INDIANAPOLIS, July 27, 2011 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)
today announced the launch of a physician payment registry
(www.lillyphysicianpaymentregistry.com) to help the public better understand how
the company works with U.S. physicians and compensates them for their services -
and how these collaborations benefit patient care.

The website allows visitors to search payments to individual U.S.-based
physicians and the institutions or research organizations that receive payments
on behalf of a physician. Payments are reported in several categories -
including research-related payments, educational programs and other services,
such as commercial consulting. The registry also discloses non-cash forms of
value provided (such as business meals), as well as travel expenses paid by
Lilly when a physician is performing services for the company.

These disclosures are part of Lilly’s obligations under its Corporate Integrity
Agreement with the federal government, and are consistent with the company’s
philosophy that improved transparency around collaborations with physicians can
help strengthen the public’s trust in the pharmaceutical industry.

“When health care professionals work together with the pharmaceutical industry,
patients benefit from our combined expertise,” said Jack Harris, M.D., vice
president for Lilly’s U.S. Medical Division. “Through these collaborations, we
are able to develop innovative medicines, improve health education and better
understand patients’ needs. Without our joint efforts, new medicines could never
reach the millions of patients who need better treatment options for diseases
such as cancer, diabetes, depression and Alzheimer’s.”

The majority of payments reported on the registry (63 percent) are related to
research, including clinical studies for investigational medicines. These
studies evaluate the safety and effectiveness of potential medicines — critical
information that must be gathered to understand whether a treatment works, is
safe and meets the rigorous regulatory standards for bringing new medicines to
patients.

“Much of our research and development costs are related to the significant care,
testing and monitoring of patients in clinical studies,” Dr. Harris said. “These
payments cover everything from X-ray and lab work to the costs associated with
physician and staff time.”

Clinical study payments are made to an institution, such as a hospital or
university, or a principal investigator (the physician overseeing patients in
the study) to cover all the costs associated with the clinical study. In most
cases, Lilly does not know the amount of compensation, if any, that the
principal investigator receives from the institution for involvement in the
study.

The largest cumulative payment reported on the Lilly registry is to Harvard
Clinical Research Institute (HCRI), a not-for-profit academic clinical research
organization, for $767,564, related to a study requested by the U.S. Food and
Drug Administration (FDA) that illustrates a unique collaboration among the FDA,
HCRI and cardiovascular drug and device manufacturers. Called the DAPT Study
(Dual Antiplatelet Therapy), this multinational, multicenter study was initiated
in response to an FDA request for post-market studies of drug-eluting coronary
stents that would yield sufficient data to answer important public health
questions.

As the Investigational Device Exemption (IDE) sponsor for the DAPT Study, HCRI
is responsible for study management and the independent analysis of the
resulting data, and as such, has received funding support from each of the drug
and device manufacturers. The DAPT Study’s principal investigator is not an
employee of HCRI, has received no direct compensation from Lilly or HCRI for the
conduct of this study or otherwise, and has no discretionary control over any
portion of the funds paid by Lilly in support of the study.

Registry Payment overview

For the period Jan. 1-March 31, 2011, Lilly’s registry reports payments and
non-cash forms of value totaling $48.1 million to 45,440 physicians and/or 1,827
health care organizations. The majority (63 percent) was spent on
research-related payments. Educational programs (28 percent), business meals (4
percent), business travel and other value (4 percent) and other services (1
percent) accounted for the remainder of reported data.

(Photo: http://photos.prnewswire.com/prnh/20110727/DE42457 )

Additional information about the Physician Payment Registry can be found on the
website (www.lillyphysicianpaymentregistry.com).

User-friendly database allows for multiple search options

The user-friendly interface of the registry allows individuals to easily sort
the full report by entity paid, physician, state or total. Keyword searching is
supported through an advanced search and sort option. Results are categorized by
payments, non-cash forms of value and total amount. Visitors can download a PDF
version of the full report or easily print the output of search results. The
data also can be accessed on mobile devices.

The registry website also gives an overview of Lilly’s work with physicians and
the process of bringing medicines to patients, and provides answers to common
questions about the registry and what is reported.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information – for some of the world’s most urgent medical
needs. Additional information about Lilly is available at www.lilly.com.

C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company